PPAR-γ agonists are reported to inhibit components of the insulin growth factor 1 (IGF1) pathway and modulate the activity of AMP-activated protein kinase (AMPK) pathway to reduce cancer risk.19 The gene discussed is PPARG; the disease is cancer.